Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Dec;27(12):2184-2195.
doi: 10.1093/annonc/mdw410. Epub 2016 Sep 28.

Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis

C Coyle  1 , F H Cafferty  2 , C Vale  2 , R E Langley  2
Affiliations
Meta-Analysis

Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis

C Coyle et al. Ann Oncol. 2016 Dec.

Abstract

Background: Metformin use has been associated with a reduced risk of developing cancer and an improvement in overall cancer survival rates in meta-analyses, but, to date, evidence to support the use of metformin as an adjuvant therapy in individual cancer types has not been presented.

Patients and methods: We systematically searched research databases, conference abstracts and trial registries for any studies reporting cancer outcomes for individual tumour types in metformin users compared with non-users, and extracted data on patients with early-stage cancer. Studies were assessed for design and quality, and a meta-analysis was conducted to quantify the adjuvant effect of metformin on recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS), to inform future trial design.

Results: Of 7670 articles screened, 27 eligible studies were identified comprising 24 178 participants, all enrolled in observational studies. In those with early-stage colorectal cancer, metformin use was associated with a significant benefit in all outcomes [RFS hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.47-0.85; OS HR 0.69, CI 0.58-0.83; CSS HR 0.58, CI 0.39-0.86]. For men with early-stage prostate cancer, metformin was associated with significant, or borderline significant, benefits in all outcomes (RFS HR 0.83, CI 0.69-1.00; OS HR 0.82, CI 0.73-0.93; CSS HR 0.58, CI 0.37-0.93); however, there was significant heterogeneity between studies. The data suggest that prostate cancer patients treated with radical radiotherapy may benefit more from metformin (RFS HR 0.45, CI 0.29-0.70). In breast and urothelial cancer, no significant benefits were identified. Sufficient data were not available to conduct analyses on the impact of metformin dose and duration.

Conclusions: Our findings suggest that metformin could be a useful adjuvant agent, with the greatest benefits seen in colorectal and prostate cancer, particularly in those receiving radical radiotherapy, and randomised, controlled trials which investigate dose and duration, alongside efficacy, are advocated.

Keywords: adjuvant; breast cancer; colorectal cancer; metformin; prostate cancer; repurposing.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA study selection diagram.
Figure 2.
Figure 2.
Colorectal cancer outcomes according to metformin use.
Figure 3.
Figure 3.
Prostate cancer outcomes according to metformin use.
Figure 4.
Figure 4.
Prostate cancer recurrence-free survival according to metformin use for different treatment groups.
Figure 5.
Figure 5.
Breast cancer outcomes according to metformin use.
Figure 6.
Figure 6.
Urothelial cancer outcomes according to metformin use.
See this image and copyright information in PMC

References

    1. CRUK. Cancer Research UK Cancer Statistics, All Cancers Combined. http://publications.cancerresearchuk.org/downloads/Product/CS_KF_ALLCANC... (10 January 2016, date last accessed).
    1. Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet 2015; 385: 1206–1218. - PubMed
    1. Langley RE, Burdett S, Tierney JF et al. . Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer 2011; 105: 1107–1113. - PMC - PubMed
    1. Gilbert DC, Vale C, Haire R et al. . Repurposing vitamin D as an anticancer drug. Clin Oncol (R Coll Radiol) 2016; 28: 36–41. - PubMed
    1. Coleman R, Powles T, Paterson A et al. . Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386: 1353–1361. - PubMed